Compounds > rosiglitazone

Page last updated: 2024-08-25

rosiglitazone and pravastatin

rosiglitazone has been researched along with pravastatin in 14 studies

Research

Studies (14)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	6 (42.86)	29.6817
2010's	8 (57.14)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H	1
Lombardo, F; Obach, RS; Waters, NJ	1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV	1
Honda, K; Izumi, T; Miyaji, Y; Nakayama, S; Okazaki, O; Okudaira, N; Shiosakai, K; Sugiyama, D; Suzuki, W; Takakusa, H; Watanabe, A	1
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR	1
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Diamond, RH; Forman, LM; Simmons, DA	1
Eng, C; Planchon, SM; Teresi, RE; Waite, KA	1
Bachmakov, I; Fromm, MF; Glaeser, H; König, J	1
Li, HB	1
Gad, HI	1

Reviews

1 review(s) available for rosiglitazone and pravastatin

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Other Studies

13 other study(ies) available for rosiglitazone and pravastatin

Article	Year
Identifying off-target effects and hidden phenotypes of drugs in human cells. Nature chemical biology, 2006, Volume: 2, Issue:6 Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship	2006
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Physicochemical determinants of human renal clearance. Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15 Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight	2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3 Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations	2010
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites. Drug metabolism and disposition: the biological fate of chemicals, 2011, Volume: 39, Issue:7 Topics: Glutathione; Pharmacology; Sulfur Radioisotopes	2011
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. Journal of medicinal chemistry, 2012, May-24, Volume: 55, Issue:10 Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection	2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10 Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding	2012
Hepatic failure in a patient taking rosiglitazone. Annals of internal medicine, 2000, Jan-18, Volume: 132, Issue:2 Topics: Aged; Combined Modality Therapy; Coronary Disease; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemic Agents; Ischemia; Liver; Liver Failure; Male; Monitoring, Physiologic; Pravastatin; Rosiglitazone; Thiazoles; Thiazolidinediones; Verapamil	2000
Regulation of the PTEN promoter by statins and SREBP. Human molecular genetics, 2008, Apr-01, Volume: 17, Issue:7 Topics: Cell Line; Electrophoretic Mobility Shift Assay; Fatty Acids, Monounsaturated; Fluvastatin; Gene Expression Regulation; Genes, Reporter; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; PPAR gamma; Pravastatin; Promoter Regions, Genetic; PTEN Phosphohydrolase; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Simvastatin; Sterol Regulatory Element Binding Protein 1; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Up-Regulation	2008
Interaction of oral antidiabetic drugs with hepatic uptake transporters: focus on organic anion transporting polypeptides and organic cation transporter 1. Diabetes, 2008, Volume: 57, Issue:6 Topics: Administration, Oral; Animals; Biological Transport; Carbamates; Cell Line; Dogs; Hepatocytes; Humans; Hypoglycemic Agents; Kidney; Kinetics; Liver; Liver-Specific Organic Anion Transporter 1; Metformin; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Piperidines; Pravastatin; Recombinant Proteins; Rosiglitazone; Solute Carrier Organic Anion Transporter Family Member 1B3; Thiazolidinediones	2008
[Pravastatin and rosiglitazone combination therapy upgrades the expression of ABCA1 in THP-1 macrophages]. Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology, 2011, Volume: 27, Issue:1 Topics: Anticholesteremic Agents; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Cell Line; Drug Synergism; Humans; Macrophages; PPAR gamma; Pravastatin; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Up-Regulation	2011
Does combined peroxisome proliferator-activated receptors-agonist and pravastatin therapy attenuate the onset of diabetes-induced experimental nephropathy? Saudi medical journal, 2014, Volume: 35, Issue:11 Topics: Animals; Creatinine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Glycated Hemoglobin; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Intercellular Adhesion Molecule-1; Kidney; Lipid Peroxides; Peroxisome Proliferator-Activated Receptors; Pravastatin; Rats; Rosiglitazone; Thiazolidinediones; Transferrin; Tumor Necrosis Factor-alpha	2014